Kura Oncology, Inc. (NASDAQ:KURA) Receives $29.20 Consensus Target Price from Brokerages

Kura Oncology, Inc. (NASDAQ:KURA) has been given an average rating of “Moderate Buy” by the six ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $29.20.

KURA has been the topic of a number of recent analyst reports. JMP Securities restated a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a research note on Monday, August 12th. HC Wainwright reissued a “buy” rating and issued a $32.00 target price on shares of Kura Oncology in a research report on Monday, August 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research report on Monday, September 9th. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and dropped their price target for the company from $26.00 to $19.00 in a research note on Monday, October 14th. Finally, StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, August 22nd.

Kura Oncology Stock Down 0.5 %

Kura Oncology stock opened at $18.00 on Wednesday. The business has a fifty day moving average price of $19.51 and a 200-day moving average price of $20.19. Kura Oncology has a 1-year low of $7.41 and a 1-year high of $24.17. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -8.29 and a beta of 0.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. The firm’s revenue was up .0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.53) EPS. Equities research analysts forecast that Kura Oncology will post -2.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds have recently added to or reduced their stakes in KURA. Susquehanna Fundamental Investments LLC acquired a new position in shares of Kura Oncology in the 1st quarter valued at about $507,000. Hennion & Walsh Asset Management Inc. lifted its holdings in Kura Oncology by 42.3% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 181,674 shares of the company’s stock valued at $3,875,000 after acquiring an additional 54,031 shares during the period. Assenagon Asset Management S.A. lifted its holdings in Kura Oncology by 50.1% in the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after acquiring an additional 577,732 shares during the period. Vanguard Group Inc. boosted its position in Kura Oncology by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after purchasing an additional 28,212 shares in the last quarter. Finally, Sofinnova Investments Inc. grew its stake in shares of Kura Oncology by 64.4% during the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock worth $16,992,000 after purchasing an additional 323,303 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.